TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19734776
Drug: Long-term rhGH
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term rhGH at 0.05, 0.1, or 0.2 mg/kg/d
Study: 19734776
Drug: Long-term rhGH
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term rhGH at 0.2 mg/kg/d
Study: 19734776
Drug: Long-term rhGH
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term rhGH at 0.1 mg/kg/d
Study: 19734776
Drug: Long-term rhGH
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term rhGH at 0.1 and 0.2 mg/kg/d
Study: 8880048
Drug: tramadol controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol controlled release 150 mg (TCR150)
Study: 8880048
Drug: tramadol controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol controlled release 100 mg (TCR100)
Study: 8880048
Drug: tramadol standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol standard formulation (T100)
Study: 2051734
Drug: Lovastatin (1st
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (1st month 20 mg; 2nd and 3rd months 40 mg day‐1)
Study: 2051734
Drug: Simvastatin (1st
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (1st month 10 mg; 2nd month 20 mg; 3rd month 40 mg day‐1)
Study: 31495201
Drug: BL-8040 +
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-8040 + G-CSF
Study: 31495201
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + G-CSF
Study: 22349746
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline infusion 1.5 mL/kg
Study: 15960429
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g alcohol/kg body weight (females: 10% less)
Study: 15960429
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g alcohol/kg body weight (females: 10% less)
Study: 28972192
Drug: Tadalafil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 0.3 mg·kg‐1·d‐1
Study: 28972192
Drug: Tadalafil 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 0.6 mg·kg‐1·d‐1
Study: 28972192
Drug: Tadalafil (low-dose)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil (low-dose)
Study: 28972192
Drug: Tadalafil (high-dose)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil (high-dose)
Study: 26939334
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection at Zusanli (ST 36) combined with electroacupuncture (EA) at Hegu (LI 4) and Sanyinjiao (SP 6)
Study: 26939334
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection and EA
Study: 22068465
Drug: Natural interferon
Normalized name: interferon beta natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural interferon α (3 million to 6 million units) administered intramuscularly 3 times a week for 1 year
Study: 17583373
Drug: Prednisolone plus
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone plus intravenous cyclophosphamide pulse therapy (P/PC)
Study: 15024666
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC) - 200 mg of ascorbic acid twice a day for 14 days prior to exercise and for 3 days after exercise
Study: 15024666
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) - identical capsules containing 200 mg lactose
Study: 9688064
Drug: New 50
Normalized name: TITANIUM DIOXIDE 50 mg in 1 mL / ZINC OXIDE 150 mg in 1 mL TOPICAL LOTION [La Roche Posay New 50 Body and Face SPF 50 Mineral Anthelios Gentle 100 percent mineral UV filters Soft finish with Cell Ox Shield]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 50 mg tablet formulation
Study: 9688064
Drug: Old 50
Normalized name: Pro-Tec Gold 50 MG/ML Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old 50 mg tablet formulation
Study: 9688064
Drug: Suspension containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension containing 50 mg/ml of primidone
Study: 9688064
Drug: New 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 250 mg tablet formulation
Study: 9688064
Drug: Old 250
Normalized name: OLDENLANDIA DIFFUSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old 250 mg tablet formulation (two lots)
Study: 9688064
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tablet from a second manufacturer
Study: 2510223
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg i.v.
Study: 2510223
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml 0.9% NaCl)
Study: 355026
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) 375 mg/day
Study: 355026
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) 750 mg/day
Study: 355026
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) 1,500 mg/day
Study: 355026
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) 3,000 mg/day
Study: 355026
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA) 1,500 mg/day or 17‐24 mg/kg body weight
Study: 31944270
Drug: Iontophoretic delivery
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoretic delivery of methotrexate, once weekly for 6 sittings.
Study: 31944270
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% ointment, twice daily for 6 weeks.
Study: 31240472
Drug: Plitidepsin 5
Normalized name: Plitidepsine
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 5 mg/m2 on D1 and D15 plus Dexamethasone 40 mg on D1, D8, D15, and D22 (arm A)
Study: 31240472
Drug: Dexamethasone 40
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg on D1, D8, D15, and D22 (arm B)
Study: 26228390
Drug: Telehealth program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth program (MASTERY©) using a mobile application (Breathe-easy©) and a Bluetooth-enabled device (COPD-6®) for self-monitoring of lung function (FEV1, FEV6) twice daily, recording asthma symptoms and medication usage weekly, and a written asthma action plan (WAAP)
Study: 17693902
Drug: Intranasal E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal E2/NET 175 microg/275 mug
Study: 17693902
Drug: Oral E2/NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2/NET acetate 1 mg/0.5 mg
Study: 17297830
Drug: Propofol (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.45 mg x kg(‐1))
Study: 17297830
Drug: Ketamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine plus Propofol (0.45 mg x kg(‐1) of propofol plus 0.25 mg x kg(‐1) of ketamine)
Study: 10625080
Drug: Indomethacin (0.20‐0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.20‐0.25 mg/kg, 12 hourly)
Study: 10625080
Drug: Ibuprofen (5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (5‐10 mg/kg, 24 hourly)
Study: 10625080
Drug: Indomethacin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (after 24-h dose)
Study: 10625080
Drug: Indomethacin (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (after 48-h dose of saline)
Study: 10625080
Drug: Ibuprofen (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (after 24-h and 48-h doses)
Study: 1591054
Drug: Formestane 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane 62.5 mg
Study: 1591054
Drug: Formestane 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane 125 mg
Study: 29879277
Drug: Oral Valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Valproic Acid (VPA) 500 mg to 1000 mg daily for 12 months
Study: 25015756
Drug: Thrombin-based topical
Normalized name: thrombin Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-based topical hemostatic matrix
Study: 18582257
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion (n = 92)
Study: 7861597
Drug: Flumazenil (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.25 mg given initially, followed by another 0.25 mg 2 hours later)
Study: 7861597
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of flumazenil (0.25 mg in 250 ml of lactated Ringer's solution for 2 hours)
Study: 2618844
Drug: Self-ratings after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-ratings after exposure to drug stimuli
Study: 21313894
Drug: M 1.0
Normalized name: Pitavastatin Calcium 1.045mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: M 1.0 (lidocaine 5% and midazolam 1 mg)
Study: 21313894
Drug: M 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: M 0.5 (lidocaine 5% and midazolam 0.5 mg)
Study: 7577198
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with doxorubicin and cisplatin
Study: 6459839
Drug: L-tryptophan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (5 g po as a single dose)
Study: 6459839
Drug: L-tryptophan combined
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan combined with nicotinamide (a tryptophan pyrrolase inhibitor) administered for 1-3 weeks
Study: 25326008
Drug: Dopamine 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine 7 µg/kg/min (Group D)
Study: 25326008
Drug: Methoxamine 1
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 1 µg/kg/min (Group M1)
Study: 25326008
Drug: Methoxamine 2
Normalized name: methoxamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine 2 µg/kg/min (Group M2)
Study: 25326008
Drug: Methoxamine 3
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 3 µg/kg/min (Group M3)
Study: 17102802
Drug: Bicalutamide (Casodex)
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide (Casodex) 150 mg plus standard care
Study: 15831604
Drug: Secondary preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary preventive treatments
Study: 14601488
Drug: Serum/plasma levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum/plasma levels of insulin (I), insulin‐like growth hormone‐1 (IGF‐1), luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2), and free triiodothyronine (fT3) in AN
Study: 27939204
Drug: Glycopyrrolate (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (8 μg/kg 8 hourly)
Study: 10714911
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of estradiol valerate plus 200 mg of enanthate of dihydroandrosterone im monthly (Group A)
Study: 10714911
Drug: 50 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/day of transdermal 17-b-estradiol continuously (Group E)
Study: 10714911
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of tibolone every day (Group T)
Study: 10714911
Drug: Treatment-free control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free control group (Group C)
Study: 8176626
Drug: Ticlopidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (200 mg daily)
Study: 28185784
Drug: Integrated Neurocognitive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Neurocognitive Therapy (INT)
Study: 21307816
Drug: baclofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: baclofen (10 mg)
Study: 21307816
Drug: meclizine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: meclizine (50 mg)
Study: 21307816
Drug: cinnarizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinnarizine (20 mg) + dimenhydrinate (40 mg)
Study: 21307816
Drug: promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine (25 mg) + dextro‐amphetamine (5 mg)
Study: 18294083
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (72 mg)
Study: 16950962
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended release (30 mg)
Study: 15597521
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) 1000 mg qd
Study: 15597521
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) 1500 mg qd
Study: 15597521
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ddI plus HU
Study: 11374699
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA) 25-30 mg/kg per day
Study: 9018022
Drug: Remoxipride (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (150 mg)
Study: 9018022
Drug: Sulpiride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (300 mg)
Study: 3525023
Drug: PY 108-068
Normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY 108-068 (75 mg)
Study: 24871787
Drug: DA-9601 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-9601 (60 mg, thrice daily)
Study: 24871787
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 μg, thrice daily)
Study: 20537558
Drug: Scopolamine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine patch (1.5 mg)
Study: 18237269
Drug: 90-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-microg dose of H5N1 influenza vaccine
Study: 18237269
Drug: 45-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45-microg dose of H5N1 influenza vaccine
Study: 18237269
Drug: 15-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-microg dose of H5N1 influenza vaccine
Study: 18237269
Drug: 7.5-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5-microg dose of H5N1 influenza vaccine
Study: 18237269
Drug: H5N1 influenza
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 influenza vaccine (third dose)
Study: 12830564
Drug: Specialist outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist outpatient treatment in specialist eating disorder clinics.
Study: 31283835
Drug: Pre-operative CRP
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative CRP ≥5 mg/dL
Study: 28132701
Drug: SBIRT intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SBIRT intervention (screening, brief intervention, and referral to treatment)
Study: 24879388
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) with 25g glucose
Study: 24879388
Drug: Isoglycaemic intravenous
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycaemic intravenous glucose infusion (IIGI)
Study: 24879388
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) with 75g and 125g glucose
Study: 11772900
Drug: Diabetes medication
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes medication or weight-reduction program for patients with IGT
Study: 9682550
Drug: Subgingival scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival scaling using ultrasonic scalers and local anaesthesia plus systemic metronidazole (200 mg tds for 7 days)
Study: 9682550
Drug: Subgingival scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival scaling using ultrasonic scalers and local anaesthesia plus two applications of 25% metronidazole gel one week apart
Study: 9234259
Drug: 125I‐B72.3 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I‐B72.3 (1 mg)
Study: 9234259
Drug: 125I‐B72.3 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I‐B72.3 (20 mg)
Study: 9234259
Drug: 131I‐CC49 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I‐CC49 (1 mg)
Study: 9234259
Drug: 131I‐CC49 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I‐CC49 (20 mg)
Study: 2920999
Drug: Propranolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (15 mg intravenous single dose)
Study: 2920999
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg per day chronic oral administration)
Study: 2920999
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 mg intravenous single dose)
Study: 2920999
Drug: Placebo (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (160 mg per day chronic oral administration)
Study: 28062685
Drug: Predictive scoring
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive scoring model for all-cause 30 day mortality based on logistic regression including factors such as age >50 years, infection due to Klebsiella spp., source other than urinary tract, fatal underlying disease, Pitt score >3, severe sepsis or septic shock at presentation, and inappropriate early targeted therapy.
Study: 23914988
Drug: Metyrapone 500
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone 500 mg twice daily
Study: 21565593
Drug: Psychophysiological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychophysiological treatment (PT), 10 sessions, manualized, individually-administered
Study: 21565593
Drug: Psychophysiological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychophysiological treatment (PT)
Study: 19593170
Drug: Algorithm-guided standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided standardized stepwise drug treatment regimen (SSTR)
Study: 17227922
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (optimized medical therapy)
Study: 31823111
Drug: No-treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment condition (control)
Study: 26120980
Drug: Baclosan in
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclosan in combination with standard therapy
Study: 21940214
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus rituximab
Study: 21940214
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus rituximab (favourable subgroup, IPI=0, no bulk)
Study: 21940214
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (less favourable subgroup, IPI=1 or bulk, or both)
Study: 19069803
Drug: Magneto-laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magneto-laser therapy
Study: 1294818
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment administered during RA remission
Study: 6199450
Drug: Cibenzoline (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibenzoline (maximum dose)
Study: 29661916
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with real-time continuous glucose monitoring (RT-CGM)
Study: 29661916
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG)
Study: 25886108
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg with dexamethasone 8 mg
Study: 25886108
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg with dexamethasone 8 mg
Study: 25886108
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg alone (Control Group)
Study: 18506738
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ambroxol
Study: 15937908
Drug: Fulvestrant (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (250 mg monthly)
Study: 12473476
Drug: Sterillium Gel
Normalized name: Trillium erectum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterillium Gel (85% ethanol-based) applied under occlusive patch during induction phase (nine applications over three weeks) and one application during challenge phase.
Study: 12473476
Drug: Sterillium Gel
Normalized name: Trillium erectum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterillium Gel applied twice a day to the forearm for 14 days.
Study: 9838800
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (20 g/day, 5 days/week)
Study: 7814240
Drug: Low-fat spread
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat spread (40% fat wt/wt) containing 8 g of fish oil per 100 g of product (Group B)